{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:21:04Z","timestamp":1792131664634,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41401-026-01754-4","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:58:55Z","timestamp":1771498735000},"page":"1643-1659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1"],"prefix":"10.1038","volume":"47","author":[{"given":"Shuai-shuai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-ru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-meng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1754_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0264-8","volume":"8","author":"I Gra\u00e7a","year":"2016","unstructured":"Gra\u00e7a I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jer\u00f3nimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 2016;8:98.","journal-title":"Clin Epigenetics"},{"key":"1754_CR2","first-page":"59","volume":"55","author":"HZ Li","year":"2017","unstructured":"Li HZ, Zhang YS. Review of hot topics in the diagnosis and treatment of prostate cancer in 2016. Zhonghua Wai Ke Za Zhi. 2017;55:59\u201362.","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"1754_CR3","doi-asserted-by":"crossref","unstructured":"Gagnidze K, Pfaff DW. Epigenetic mechanisms: DNA methylation and histone protein modification. In: Pfaff DW, Volkow ND, Rubenstein J, Editors. Neuroscience in the 21st century: from basic to clinical. New York: Springer; 2020. p 1\u201340.","DOI":"10.1007\/978-1-4614-6434-1_69-3"},{"key":"1754_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-017-0467-0","volume":"18","author":"Y Pan","year":"2018","unstructured":"Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18:1\u201314.","journal-title":"Clin Exp Med"},{"key":"1754_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383:650\u201363.","journal-title":"N Engl J Med"},{"key":"1754_CR6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fphar.2020.00992","volume":"11","author":"SH Akone","year":"2020","unstructured":"Akone SH, Ntie-Kang F, Stuhldreier F, Ewonkem MB, Noah AM, Mouelle SEM, et al. Natural products impacting DNA methyltransferases and histone deacetylases. Front Pharmacol. 2020;11:992.","journal-title":"Front Pharmacol"},{"key":"1754_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2025.2491316","volume":"20","author":"S Roy","year":"2025","unstructured":"Roy S, Deka D, Kondaveeti SB, Ayyadurai P, Siripragada S, Philip N, et al. An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update. Epigenetics. 2025;20:2491316.","journal-title":"Epigenetics"},{"key":"1754_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115467","volume":"417","author":"R Irshad","year":"2021","unstructured":"Irshad R, Husain M. Natural products in the reprogramming of cancer epigenetics. Toxicol Appl Pharmacol. 2021;417:115467.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1754_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10565-025-10054-2","volume":"41","author":"S Bakrim","year":"2025","unstructured":"Bakrim S, El Omari N, El Yaagoubi OM, Khalid A, Abdalla AN, Hamza SMA, et al. Epi-nutrients for cancer prevention: molecular mechanisms and emerging insights. Cell Biol Toxicol. 2025;41:116.","journal-title":"Cell Biol Toxicol"},{"key":"1754_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fphar.2020.00151","volume":"11","author":"G Manda","year":"2020","unstructured":"Manda G, Rojo AI, Mart\u00ednez-Klimova E, Pedraza-Chaverri J, Cuadrado A. Nordihydroguaiaretic acid: from herbal medicine to clinical development for cancer and chronic diseases. Front Pharmacol. 2020;11:151.","journal-title":"Front Pharmacol"},{"key":"1754_CR11","doi-asserted-by":"publisher","first-page":"86225","DOI":"10.18632\/oncotarget.13368","volume":"7","author":"X Li","year":"2016","unstructured":"Li X, Fan S, Pan X, Xiaokaiti Y, Duan J, Shi Y, et al. Nordihydroguaiaretic acid impairs prostate cancer cell migration and tumor metastasis by suppressing neuropilin 1. Oncotarget. 2016;7:86225\u201338.","journal-title":"Oncotarget"},{"key":"1754_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"key":"1754_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/cas.16186","volume":"115","author":"Y Lai","year":"2024","unstructured":"Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D, et al. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Sci. 2024;115:2220\u201334.","journal-title":"Cancer Sci"},{"key":"1754_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/bjc.2011.551","volume":"106","author":"CJ Chang","year":"2012","unstructured":"Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106:243\u20137.","journal-title":"Br J Cancer"},{"key":"1754_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-023-00405-2","volume":"12","author":"B Wang","year":"2023","unstructured":"Wang B, Liu Y, Liao Z, Wu H, Zhang B, Zhang L. EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies. Exp Hematol Oncol. 2023;12:52.","journal-title":"Exp Hematol Oncol"},{"key":"1754_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"1754_CR17","doi-asserted-by":"publisher","first-page":"W96","DOI":"10.1093\/nar\/gkq418","volume":"38","author":"V Kaimal","year":"2010","unstructured":"Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res. 2010;38:W96\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"1754_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624\u20139.","journal-title":"Nature"},{"key":"1754_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ajur.2024.09.007","volume":"12","author":"S Koubardas","year":"2025","unstructured":"Koubardas S, Goutas D, Mani I, Krikou E, Mpatsi O, Gakiopoulou H, et al. Investigation of the clinical significance of the expression of immunohistochemical biomarkers Enhancer of zeste homolog 2 and Forkhead box M1 in localized prostate cancer tissue: a Greek retrospective study. Asian J Urol. 2025;12:357\u201365.","journal-title":"Asian J Urol"},{"key":"1754_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/sj.onc.1210774","volume":"27","author":"M Nuytten","year":"2008","unstructured":"Nuytten M, Beke L, Van Eynde A, Ceulemans H, Beullens M, Van Hummelen P, et al. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene. 2008;27:1449\u201360.","journal-title":"Oncogene"},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3390\/biom12111617","volume":"12","author":"TQ Du","year":"2022","unstructured":"Du TQ, Liu R, Zhang Q, Luo H, Liu Z, Sun S, et al. EZH2 as a prognostic factor and its immune implication with molecular characterization in prostate cancer: an integrated multi-omics in silico analysis. Biomolecules. 2022;12:1617.","journal-title":"Biomolecules"},{"key":"1754_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1158\/2159-8290.CD-24-0186","volume":"14","author":"RL Paolini","year":"2024","unstructured":"Paolini RL, Souroullas GP. The cell cycle: a key to unlock EZH2-targeted therapy resistance. Cancer Discov. 2024;14:903\u20135.","journal-title":"Cancer Discov"},{"key":"1754_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06571-7","volume":"23","author":"M Liu","year":"2025","unstructured":"Liu M, Zhang J, Zhang T, Zheng Q, Li S. Nordihydroguaiaretic acid inhibits bladder cancer metastasis through suppression of \u03b11,3-mannosyltransferase expression and LRFN4 N-glycosylation. J Transl Med. 2025;23:733.","journal-title":"J Transl Med"},{"key":"1754_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113688","volume":"43","author":"XM Li","year":"2024","unstructured":"Li XM, Yang Y, Jiang FQ, Hu G, Wan S, Yan WY, et al. Histone lactylation inhibits RAR\u03b3 expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling. Cell Rep. 2024;43:113688.","journal-title":"Cell Rep"},{"key":"1754_CR25","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323\u201335.","journal-title":"EMBO J"},{"key":"1754_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2012.02.040","volume":"683","author":"XY Pan","year":"2012","unstructured":"Pan XY, Guo H, Han J, Hao F, An Y, Xu Y, et al. Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol. 2012;683:27\u201334.","journal-title":"Eur J Pharmacol"},{"key":"1754_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2007.11.031","volume":"13","author":"TC Hallstrom","year":"2008","unstructured":"Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell. 2008;13:11\u201322.","journal-title":"Cancer Cell"},{"key":"1754_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1083\/jcb.201411128","volume":"211","author":"Z Zou","year":"2015","unstructured":"Zou Z, Chen J, Liu A, Zhou X, Song Q, Jia C, et al. mTORC2 promotes cell survival through c-Myc-dependent up-regulation of E2F1. J Cell Biol. 2015;211:105\u201322.","journal-title":"J Cell Biol"},{"key":"1754_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","volume":"175","author":"X Huang","year":"2018","unstructured":"Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186\u201399.e19.","journal-title":"Cell"},{"key":"1754_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00262-013-1500-0","volume":"63","author":"B Chaudhary","year":"2014","unstructured":"Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother. 2014;63:81\u201399.","journal-title":"Cancer Immunol Immunother"},{"key":"1754_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ardp.201400159","volume":"347","author":"J Hern\u00e1ndez-Dami\u00e1n","year":"2014","unstructured":"Hern\u00e1ndez-Dami\u00e1n J, And\u00e9rica-Romero AC, Pedraza-Chaverri J. Paradoxical cellular effects and biological role of the multifaceted compound nordihydroguaiaretic acid. Arch Pharm (Weinheim). 2014;347:685\u201397.","journal-title":"Arch Pharm (Weinheim)"},{"key":"1754_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/pcmr.12280","volume":"28","author":"J Tiffen","year":"2015","unstructured":"Tiffen J, Gallagher SJ, Hersey P. EZH2: an emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell Melanoma Res. 2015;28:21\u201330.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1754_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cytogfr.2016.02.001","volume":"31","author":"MG Ertosun","year":"2016","unstructured":"Ertosun MG, Hapil FZ, Osman Nidai O. E2F1 transcription factor and its impact on growth factor and cytokine signaling. Cytokine Growth Factor Rev. 2016;31:17\u201325.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1754_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188336","volume":"1873","author":"JN Chun","year":"2020","unstructured":"Chun JN, Cho M, Park S, So I, Jeon JH. The conflicting role of E2F1 in prostate cancer: a matter of cell context or interpretational flexibility?. Biochim Biophys Acta Rev Cancer. 2020;1873:188336.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1754_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116154","volume":"267","author":"J Velez","year":"2024","unstructured":"Velez J, Dale B, Park KS, Kaniskan H, Yu X, Jin J. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2. Eur J Med Chem. 2024;267:116154.","journal-title":"Eur J Med Chem"},{"key":"1754_CR36","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4161\/auto.25879","volume":"9","author":"HY Nam","year":"2013","unstructured":"Nam HY, Han MW, Chang HW, Kim SY, Kim SW. Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence. Autophagy. 2013;9:1631\u20132.","journal-title":"Autophagy"},{"key":"1754_CR37","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21:4507.","journal-title":"Int J Mol Sci"},{"key":"1754_CR38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59:1574\u201385.","journal-title":"Leuk Lymphoma"},{"key":"1754_CR39","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.3390\/cancers13184648","volume":"13","author":"E Lhuissier","year":"2021","unstructured":"Lhuissier E, Aury-Landas J, Lent\u00e9 M, Boumediene K, Baug\u00e9 C. Co-treatment with the epigenetic drug, 3-deazaneplanocin A (DZNep) and cisplatin after DZNep priming enhances the response to platinum-based therapy in chondrosarcomas. Cancers. 2021;13:4648.","journal-title":"Cancers"},{"key":"1754_CR40","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","volume":"26","author":"C Sarkozy","year":"2020","unstructured":"Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Culli\u00e8res-Dartigues P, et al. A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res. 2020;26:3145\u201353.","journal-title":"Clin Cancer Res"},{"key":"1754_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","volume":"22","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, et al. Combination of atezolizumab and tazemetostat in patients with relapsed\/refractory diffuse large B-cell lymphoma: results from a phase Ib study. Clin Lymphoma Myeloma Leuk. 2022;22:504\u201312.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1754_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s12276-021-00556-4","volume":"53","author":"SM Son","year":"2021","unstructured":"Son SM, Park SJ, Fernandez-Estevez M, Rubinsztein DC. Autophagy regulation by acetylation-implications for neurodegenerative diseases. Exp Mol Med. 2021;53:30\u201341.","journal-title":"Exp Mol Med"},{"key":"1754_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113694","volume":"430","author":"J Liu","year":"2023","unstructured":"Liu J. P300 increases CSNK2A1 expression, which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis. Exp Cell Res. 2023;430:113694.","journal-title":"Exp Cell Res"},{"key":"1754_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcancer.2018.01.014","volume":"54","author":"S Vivekanandhan","year":"2019","unstructured":"Vivekanandhan S, Mukhopadhyay D. Genetic status of KRAS influences transforming growth factor-beta (TGF-\u03b2) signaling: an insight into Neuropilin-1 (NRP1) mediated tumorigenesis. Semin Cancer Biol. 2019;54:72\u20139.","journal-title":"Semin Cancer Biol"},{"key":"1754_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1084\/jem.20111424","volume":"209","author":"P Hamerlik","year":"2012","unstructured":"Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al. Autocrine VEGF-VEGFR2-neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209:507\u201320.","journal-title":"J Exp Med"},{"key":"1754_CR46","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1038\/onc.2009.204","volume":"28","author":"T Bagci","year":"2009","unstructured":"Bagci T, Wu JK, Pfannl R, Ilag LL, Jay DG. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene. 2009;28:3537\u201350.","journal-title":"Oncogene"},{"key":"1754_CR47","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1038\/sj.onc.1210348","volume":"26","author":"B Hu","year":"2007","unstructured":"Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF\/SF autocrine pathway. Oncogene. 2007;26:5577\u201386.","journal-title":"Oncogene"},{"key":"1754_CR48","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/0008-5472.CAN-11-3907","volume":"72","author":"U Yaqoob","year":"2012","unstructured":"Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M, et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Res. 2012;72:4047\u201359.","journal-title":"Cancer Res"},{"key":"1754_CR49","doi-asserted-by":"publisher","first-page":"8667","DOI":"10.1158\/0008-5472.CAN-08-2614","volume":"68","author":"Y Cao","year":"2008","unstructured":"Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D, et al. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res. 2008;68:8667\u201372.","journal-title":"Cancer Res"},{"key":"1754_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11287-w","volume":"7","author":"W Liu","year":"2017","unstructured":"Liu W, Wu T, Dong X, Zeng YA. Neuropilin-1 is upregulated by Wnt\/\u03b2-catenin signaling and is important for mammary stem cells. Sci Rep. 2017;7:10941.","journal-title":"Sci Rep"},{"key":"1754_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/intimm\/dxn006","volume":"20","author":"M Yamamoto","year":"2008","unstructured":"Yamamoto M, Suzuki K, Okuno T, Ogata T, Takegahara N, Takamatsu H, et al. Plexin-A4 negatively regulates T lymphocyte responses. Int Immunol. 2008;20:413\u201320.","journal-title":"Int Immunol"},{"key":"1754_CR52","doi-asserted-by":"publisher","first-page":"e101931","DOI":"10.1371\/journal.pone.0101931","volume":"9","author":"W Chu","year":"2014","unstructured":"Chu W, Song X, Yang X, Ma L, Zhu J, He M, et al. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor-kappa B and is associated with poor prognosis in human oral squamous cell carcinoma. PLoS One. 2014;9:e101931.","journal-title":"PLoS One"},{"key":"1754_CR53","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.3390\/ijms22115992","volume":"22","author":"M Siri","year":"2021","unstructured":"Siri M, Dastghaib S, Zamani M, Rahmani-Kukia N, Geraylow KR, Fakher S, et al. Autophagy, unfolded protein response, and neuropilin-1 cross-talk in SARS-CoV-2 infection: what can be learned from other coronaviruses. Int J Mol Sci. 2021;22:5992.","journal-title":"Int J Mol Sci"},{"key":"1754_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroscience.2023.11.007","volume":"536","author":"Y He","year":"2024","unstructured":"He Y, Tang J, Zhang M, Ying J, Mu D. Human placenta derived mesenchymal stem cells transplantation reducing cellular apoptosis in hypoxic-ischemic neonatal rats by down-regulating semaphorin 3A\/neuropilin-1. Neuroscience. 2024;536:36\u201346.","journal-title":"Neuroscience"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01754-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:01:43Z","timestamp":1779440503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01754-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author Xue-jun Li\u00a0is a member of the Editorial Board of the journal Acta Pharmacologica Sinica, but she has not been involved in the peer-review or decision-making process for this manuscript.\u00a0The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}